TIGeR-PaC is Evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) Therapy Platform for the Treatment of Locally Advanced Pancreatic Cancer
Dr. Meredith Pelster, Associate Director for GI Research Across Sarah Cannon Research Institute (SCRI), Appointed Principal Investigator for TIGeR-PaC Study
LOS ALTOS, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) — RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared local drug-delivery platform, announced today that SCRI Oncology Partners in Nashville, TN, is now enrolling patients with locally advanced pancreatic cancer (LAPC) in the Company’s ongoing pivotal Phase III TIGeR-PaC clinical trial. SCRI Oncology Partners joins esteemed clinical sites throughout United States participating in the study.
The TIGeR-PaC study is using RenovoRx’s TAMPTM (Trans-Arterial Micro-Perfusion) therapy platform to evaluate the Company’s first investigational drug-device combination product candidate (intra-arterial infusion of gemcitabine via RenovoCath delivery system). TAMP utilizes pressure-mediated delivery of gemcitabine to the target tumor. The study is comparing treatment with TAMP in LAPC to the current standard-of-care (systemic intravenous chemotherapy).
“I am honored to lead the TIGeR-PaC clinical trial at SCRI Oncology Partners. My goal as a clinician is to provide the most personalized and advanced care to patients, as each cancer journey is unique, requiring an individualized care plan,” said Meredith S. Pelster, M.D., MSCI, Medical Oncologist and principal investigator for the TIGeR-PaC study at SCRI Oncology Partners as well as Associate Director of Gastrointestinal Research for SCRI. “Pancreatic cancer remains one of the most challenging cancers to treat. This important study potentially may offer patients new hope for improved survival and reduced systemic side effects.”